Shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) were up 3.4% during mid-day trading on Thursday . The company traded as high as $63.00 and last traded at $61.77, with a volume of 320,500 shares. The stock had previously closed at $59.74.

A number of analysts recently issued reports on ANIP shares. Guggenheim reissued a “buy” rating and set a $55.00 price target (up from $50.00) on shares of ANI Pharmaceuticals in a report on Saturday, May 7th. Standpoint Research downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, May 24th. Raymond James Financial Inc. assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, June 22nd. They set a “strong-buy” rating and a $68.00 price objective on the stock. Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 6th. Finally, Citigroup Inc. downgraded shares of ANI Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $49.00 price objective on the stock. in a report on Friday, July 8th. They noted that the move was a valuation call. One analyst has rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $64.00.

The company has a market cap of $689.23 million and a price-to-earnings ratio of 70.34. The firm has a 50-day moving average price of $63.40 and a 200-day moving average price of $49.30.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.34. During the same quarter last year, the company posted $0.55 earnings per share. The business had revenue of $31.30 million for the quarter, compared to analysts’ expectations of $27.63 million. The business’s quarterly revenue was up 60.5% compared to the same quarter last year. Equities analysts predict that ANI Pharmaceuticals Inc. will post $4.12 earnings per share for the current year.

In related news, insider Arthur Przybyl sold 37,455 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $66.97, for a total transaction of $2,508,361.35. Following the transaction, the insider now directly owns 200,788 shares in the company, valued at $13,446,772.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert W. Schrepfer sold 12,500 shares of the firm’s stock in a transaction on Monday, August 8th. The stock was sold at an average price of $67.06, for a total value of $838,250.00. Following the transaction, the vice president now owns 17,362 shares in the company, valued at $1,164,295.72. The disclosure for this sale can be found here.

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.